Compile Data Set for Download or QSAR
Report error Found 14 Enz. Inhib. hit(s) with all data for entry = 9715
TargetBromodomain-containing protein 4 [349-460](Human)
Tensha Therapeutics

US Patent
LigandPNGBDBM223491(US9320741, JQ6 | US10407441, Compound JQ6 | US1092...)
Affinity DataIC50: 0.240nMAssay Description:The binding activity of lead compounds with the BRD4 site 2 was determined by Alpha-assay with a 12-point dose response curveMore data for this Ligand-Target Pair
In Depth
Date in BDB:
9/6/2021
Entry Details
US Patent

TargetBromodomain-containing protein 4 [349-460](Human)
Tensha Therapeutics

US Patent
LigandPNGBDBM223492(US9320741, JQ8 | US10407441, Compound JQ8 | US1092...)
Affinity DataIC50: 0.427nMAssay Description:The binding activity of lead compounds with the BRD4 site 2 was determined by Alpha-assay with a 12-point dose response curveMore data for this Ligand-Target Pair
In Depth
Date in BDB:
9/6/2021
Entry Details
US Patent

TargetBromodomain-containing protein 4 [349-460](Human)
Tensha Therapeutics

US Patent
LigandPNGBDBM223493(US9320741, JQ13 | US10407441, Compound JQ13 | US10...)
Affinity DataIC50: 0.584nMAssay Description:The binding activity of lead compounds with the BRD4 site 2 was determined by Alpha-assay with a 12-point dose response curveMore data for this Ligand-Target Pair
In Depth
Date in BDB:
9/6/2021
Entry Details
US Patent

TargetBromodomain-containing protein 4 [44-167](Human)
Tensha Therapeutics

US Patent
LigandPNGBDBM223492(US9320741, JQ8 | US10407441, Compound JQ8 | US1092...)
Affinity DataIC50: 2.19nMAssay Description:The binding activity of lead compounds with the BRD4 site 1 was determined by Alpha-assay with a 12-point dose response curveMore data for this Ligand-Target Pair
In Depth
Date in BDB:
9/6/2021
Entry Details
US Patent

TargetBromodomain-containing protein 4 [44-167](Human)
Tensha Therapeutics

US Patent
LigandPNGBDBM223493(US9320741, JQ13 | US10407441, Compound JQ13 | US10...)
Affinity DataIC50: 2.49nMAssay Description:The binding activity of lead compounds with the BRD4 site 1 was determined by Alpha-assay with a 12-point dose response curveMore data for this Ligand-Target Pair
In Depth
Date in BDB:
9/6/2021
Entry Details
US Patent

TargetBromodomain-containing protein 4 [44-167](Human)
Tensha Therapeutics

US Patent
LigandPNGBDBM223491(US9320741, JQ6 | US10407441, Compound JQ6 | US1092...)
Affinity DataIC50: 3.48nMAssay Description:The binding activity of lead compounds with the BRD4 site 1 was determined by Alpha-assay with a 12-point dose response curveMore data for this Ligand-Target Pair
In Depth
Date in BDB:
9/6/2021
Entry Details
US Patent

TargetBromodomain-containing protein 4 [349-460](Human)
Tensha Therapeutics

US Patent
LigandPNGBDBM483491(US10925881, Name (S)-JQ35)
Affinity DataIC50: 6.13nMAssay Description:The binding activity of lead compounds with the BRD4 site 2 was determined by Alpha-assay with a 12-point dose response curveMore data for this Ligand-Target Pair
In Depth
Date in BDB:
9/6/2021
Entry Details
US Patent

TargetBromodomain-containing protein 4 [349-460](Human)
Tensha Therapeutics

US Patent
LigandPNGBDBM50365262(CHEMBL1957266 | (S)-JQ1 (1) | US9320741, (S)-JQ1 |...)
Affinity DataIC50: 14nMAssay Description:The binding activity of lead compounds with the BRD4 site 2 was determined by Alpha-assay with a 12-point dose response curveMore data for this Ligand-Target Pair
In Depth
Date in BDB:
9/6/2021
Entry Details
US Patent

TargetBromodomain-containing protein 4 [44-167](Human)
Tensha Therapeutics

US Patent
LigandPNGBDBM50365262(CHEMBL1957266 | (S)-JQ1 (1) | US9320741, (S)-JQ1 |...)
Affinity DataIC50: 18nMAssay Description:The binding activity of lead compounds with the BRD4 site 1 was determined by Alpha-assay with a 12-point dose response curveMore data for this Ligand-Target Pair
In Depth
Date in BDB:
9/6/2021
Entry Details
US Patent

TargetBromodomain-containing protein 4 [44-167](Human)
Tensha Therapeutics

US Patent
LigandPNGBDBM483491(US10925881, Name (S)-JQ35)
Affinity DataIC50: 24.3nMAssay Description:The binding activity of lead compounds with the BRD4 site 1 was determined by Alpha-assay with a 12-point dose response curveMore data for this Ligand-Target Pair
In Depth
Date in BDB:
9/6/2021
Entry Details
US Patent

TargetBromodomain-containing protein 4 [349-460](Human)
Tensha Therapeutics

US Patent
LigandPNGBDBM483490(US10925881, Name (S)-JQ33)
Affinity DataIC50: 29.5nMAssay Description:The binding activity of lead compounds with the BRD4 site 2 was determined by Alpha-assay with a 12-point dose response curveMore data for this Ligand-Target Pair
In Depth
Date in BDB:
9/6/2021
Entry Details
US Patent

TargetBromodomain-containing protein 4 [44-167](Human)
Tensha Therapeutics

US Patent
LigandPNGBDBM483490(US10925881, Name (S)-JQ33)
Affinity DataIC50: 85nMAssay Description:The binding activity of lead compounds with the BRD4 site 1 was determined by Alpha-assay with a 12-point dose response curveMore data for this Ligand-Target Pair
In Depth
Date in BDB:
9/6/2021
Entry Details
US Patent

TargetBromodomain-containing protein 4 [44-167](Human)
Tensha Therapeutics

US Patent
LigandPNGBDBM205429( (R)-JQ1 (3) | US9320741, (R)-JQ1 | US10407441, Co...)
Affinity DataIC50: 8.35E+6nMAssay Description:The binding activity of lead compounds with the BRD4 site 1 was determined by Alpha-assay with a 12-point dose response curveMore data for this Ligand-Target Pair
In Depth
Date in BDB:
9/6/2021
Entry Details
US Patent

TargetBromodomain-containing protein 4 [349-460](Human)
Tensha Therapeutics

US Patent
LigandPNGBDBM205429( (R)-JQ1 (3) | US9320741, (R)-JQ1 | US10407441, Co...)
Affinity DataIC50: 5.21E+7nMAssay Description:The binding activity of lead compounds with the BRD4 site 2 was determined by Alpha-assay with a 12-point dose response curveMore data for this Ligand-Target Pair
In Depth
Date in BDB:
9/6/2021
Entry Details
US Patent